AI assistant
Sending…
Corvus Pharmaceuticals, Inc. — Director's Dealing 2023
May 16, 2023
32755_dirs_2023-05-16_0551e73d-f418-4385-a379-9c8cccbacf36.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2023-05-15
Reporting Person: Grais Linda (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-05-15 | Common Stock | P | 10000 | $2.45 | Acquired | 10000 | Direct |
More from Corvus Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Share Issue/Capital Change
2026
May 7
Major Shareholding Notification
2026
Mar 26
Major Shareholding Notification
2026
Feb 5
Major Shareholding Notification
2026
Jan 30
Director's Dealing
2026
Jan 30
Major Shareholding Notification
2026
Jan 27
Capital/Financing Update
2026
Jan 23
Capital/Financing Update
2026
Jan 23
Capital/Financing Update
2026
Jan 20